Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 1.00
CRME's Cash-to-Debt is ranked lower than
76% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. CRME: 1.00 )
Ranked among companies with meaningful Cash-to-Debt only.
CRME' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.64  Med: 79.83 Max: No Debt
Current: 1
Equity-to-Asset 0.47
CRME's Equity-to-Asset is ranked lower than
69% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CRME: 0.47 )
Ranked among companies with meaningful Equity-to-Asset only.
CRME' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.01  Med: 0.74 Max: 0.99
Current: 0.47
-0.01
0.99
Piotroski F-Score: 3
Altman Z-Score: -6.36
Beneish M-Score: -3.06
WACC vs ROIC
-7.20%
-80.12%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -81.01
CRME's Operating Margin % is ranked higher than
55% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. CRME: -81.01 )
Ranked among companies with meaningful Operating Margin % only.
CRME' s Operating Margin % Range Over the Past 10 Years
Min: -4312.67  Med: -237.87 Max: 55.51
Current: -81.01
-4312.67
55.51
Net Margin % -105.64
CRME's Net Margin % is ranked higher than
50% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. CRME: -105.64 )
Ranked among companies with meaningful Net Margin % only.
CRME' s Net Margin % Range Over the Past 10 Years
Min: -3763.2  Med: -97.34 Max: 105.81
Current: -105.64
-3763.2
105.81
ROE % -91.51
CRME's ROE % is ranked lower than
73% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. CRME: -91.51 )
Ranked among companies with meaningful ROE % only.
CRME' s ROE % Range Over the Past 10 Years
Min: -142.44  Med: -83 Max: 116.12
Current: -91.51
-142.44
116.12
ROA % -41.00
CRME's ROA % is ranked lower than
53% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. CRME: -41.00 )
Ranked among companies with meaningful ROA % only.
CRME' s ROA % Range Over the Past 10 Years
Min: -101.59  Med: -37.63 Max: 51.35
Current: -41
-101.59
51.35
ROC (Joel Greenblatt) % -454.68
CRME's ROC (Joel Greenblatt) % is ranked lower than
51% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. CRME: -454.68 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CRME' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1657.72  Med: -773.99 Max: 1550.15
Current: -454.68
-1657.72
1550.15
3-Year Revenue Growth Rate 53.10
CRME's 3-Year Revenue Growth Rate is ranked higher than
87% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. CRME: 53.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CRME' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 34.3 Max: 227.7
Current: 53.1
0
227.7
GuruFocus has detected 5 Warning Signs with Cardiome Pharma Corp $CRME.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CRME's 30-Y Financials

Financials (Next Earnings Date: 2017-08-15 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

CRME Guru Trades in Q2 2016

Jim Simons 90,213 sh (+38.12%)
» More
Q3 2016

CRME Guru Trades in Q3 2016

Jim Simons 162,613 sh (+80.25%)
» More
Q4 2016

CRME Guru Trades in Q4 2016

Jim Simons 215,013 sh (+32.22%)
» More
Q1 2017

CRME Guru Trades in Q1 2017

Jim Simons 253,413 sh (+17.86%)
» More
» Details

Insider Trades

Latest Guru Trades with CRME

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 3741
Compare:OTCPK:HSDT, NAS:VTL, NAS:EVGN, NAS:BDSI, NAS:OMED, OTCPK:HPPI, OTCPK:IMMVF, NAS:ALBO, NAS:CDXC, NAS:PSTI, OTCPK:BNOEF, AMEX:XXII, NYSE:KDMN, NAS:ARWR, NAS:QURE, NAS:PRQR, OTCPK:VNLPY, OTCPK:CTIX, NAS:SRNE, OTCPK:CNBX » details
Traded in other countries:COM.Canada, CKO1.Germany,
Headquarter Location:Canada
Cardiome Pharma Corp is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease.

Cardiome Pharma is a Canadian company that develops drugs to treat cardiovascular diseases. The firm's lead drug, vernakalant, aims to treat atrial fibrilation, or the irregular beating of the upper chambers of the heart. The firm is developing the drug in both oral and intravenous formulations. The IV form is currently marketed in parts of the world as Brinavess. Merck had been developing the oral form, but has discontinued work on the drug.

Ratios

vs
industry
vs
history
PB Ratio 4.76
CRME's PB Ratio is ranked higher than
61% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. CRME: 4.76 )
Ranked among companies with meaningful PB Ratio only.
CRME' s PB Ratio Range Over the Past 10 Years
Min: 0.76  Med: 6.59 Max: 33.74
Current: 4.76
0.76
33.74
PS Ratio 4.97
CRME's PS Ratio is ranked higher than
81% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. CRME: 4.97 )
Ranked among companies with meaningful PS Ratio only.
CRME' s PS Ratio Range Over the Past 10 Years
Min: 2.44  Med: 15.76 Max: 303.15
Current: 4.97
2.44
303.15
EV-to-EBIT -6.24
CRME's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. CRME: -6.24 )
Ranked among companies with meaningful EV-to-EBIT only.
CRME' s EV-to-EBIT Range Over the Past 10 Years
Min: -153.4  Med: -4.8 Max: 799.5
Current: -6.24
-153.4
799.5
EV-to-EBITDA -7.38
CRME's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. CRME: -7.38 )
Ranked among companies with meaningful EV-to-EBITDA only.
CRME' s EV-to-EBITDA Range Over the Past 10 Years
Min: -19.8  Med: -5 Max: 535
Current: -7.38
-19.8
535
Current Ratio 3.61
CRME's Current Ratio is ranked lower than
52% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. CRME: 3.61 )
Ranked among companies with meaningful Current Ratio only.
CRME' s Current Ratio Range Over the Past 10 Years
Min: 1.14  Med: 6.61 Max: 97.75
Current: 3.61
1.14
97.75
Quick Ratio 3.02
CRME's Quick Ratio is ranked lower than
54% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. CRME: 3.02 )
Ranked among companies with meaningful Quick Ratio only.
CRME' s Quick Ratio Range Over the Past 10 Years
Min: 1.07  Med: 6.49 Max: 97.75
Current: 3.02
1.07
97.75
Days Inventory 265.89
CRME's Days Inventory is ranked lower than
81% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. CRME: 265.89 )
Ranked among companies with meaningful Days Inventory only.
CRME' s Days Inventory Range Over the Past 10 Years
Min: 207.89  Med: 255.33 Max: 1286.27
Current: 265.89
207.89
1286.27
Days Sales Outstanding 87.12
CRME's Days Sales Outstanding is ranked lower than
67% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. CRME: 87.12 )
Ranked among companies with meaningful Days Sales Outstanding only.
CRME' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.04  Med: 127.18 Max: 540.02
Current: 87.12
4.04
540.02
Days Payable 203.57
CRME's Days Payable is ranked higher than
85% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. CRME: 203.57 )
Ranked among companies with meaningful Days Payable only.
CRME' s Days Payable Range Over the Past 10 Years
Min: 192.5  Med: 213.12 Max: 2230.17
Current: 203.57
192.5
2230.17

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -28.70
CRME's 3-Year Average Share Buyback Ratio is ranked lower than
79% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. CRME: -28.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CRME' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -58  Med: -16.75 Max: 1.4
Current: -28.7
-58
1.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 41.30
CRME's Price-to-Net-Current-Asset-Value is ranked lower than
72% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. CRME: 41.30 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CRME' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0  Med: 7.55 Max: 279.5
Current: 41.3
0
279.5
Price-to-Tangible-Book 31.77
CRME's Price-to-Tangible-Book is ranked lower than
80% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. CRME: 31.77 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CRME' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.93  Med: 7.19 Max: 232.17
Current: 31.77
0.93
232.17
Price-to-Median-PS-Value 0.31
CRME's Price-to-Median-PS-Value is ranked higher than
94% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. CRME: 0.31 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CRME' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 2.18 Max: 109.09
Current: 0.31
0
109.09
Earnings Yield (Greenblatt) % -15.99
CRME's Earnings Yield (Greenblatt) % is ranked lower than
74% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. CRME: -15.99 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CRME' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -16.23  Med: 5.7 Max: 85271.5
Current: -15.99
-16.23
85271.5

More Statistics

Revenue (TTM) (Mil) $23.37
EPS (TTM) $ -0.93
Beta-0.33
Short Percentage of Float0.97%
52-Week Range $2.35 - 5.75
Shares Outstanding (Mil)31.93

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 30 50 83
EPS ($) -0.56 -0.14 0.59
EPS without NRI ($) -0.56 -0.14 0.59
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for CRME

Headlines

Articles On GuruFocus.com
Cardiome Reports Changes To Senior Management Team May 16 2017 
Cardiome Reports First Quarter 2017 Financial Results May 15 2017 
Cardiome Announces Amendment to Term Loan Agreement with CRG-Managed Funds May 15 2017 
Cardiome To Hold First Quarter 2017 Financial Results Conference Call On May 15 May 08 2017 
Cardiome to Present at the Bloom Burton & Co. 6th Annual Healthcare Investor Conference Apr 27 2017 
Cardiome's Partner SteadyMed Announces Successful Completion of Trevyent® Clinical Validation Study Apr 06 2017 
Cardiome's Partner SteadyMed Receives Favourable Ruling in its USPTO Inter Partes Review Apr 03 2017 
Novelion Therapeutics Appoints Mark Corrigan, M.D. to Board of Directors Mar 31 2017 
A Closer Look Into Veritas Pharma Apr 21 2016 
Cardiome Closes US$23 Million Bought Deal Financing Aug 13 2015 

More From Other Websites
Cardiome Pharma Corp. :CRME-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017 May 19 2017
Cardiome Pharma (CRME) Looks Good: Stock Moves 6.1% Higher May 18 2017
Cardiome (CRME) Q1 Loss Wider Than Expected, Sales Miss May 17 2017
Cardiome Reports Changes To Senior Management Team May 16 2017
Cardiome reports 1Q loss May 15 2017
Cardiome Reports First Quarter 2017 Financial Results May 15 2017
Investor Network: Cardiome Pharma Corp. to Host Earnings Call May 15 2017
Cardiome Announces Amendment to Term Loan Agreement with CRG-Managed Funds May 15 2017
Cardiome To Hold First Quarter 2017 Financial Results Conference Call On May 15 May 08 2017
Cardiome to Present at the Bloom Burton & Co. 6th Annual Healthcare Investor Conference Apr 27 2017
Cardiome Pharma (CRME) Jumps: Stock Adds 6.6% in Session Apr 10 2017
Cardiome's Partner SteadyMed Announces Successful Completion of Trevyent® Clinical Validation Study Apr 06 2017
Cardiome's Partner SteadyMed Receives Favourable Ruling in its USPTO Inter Partes Review Apr 03 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)